MEDIROM Healthcare Technologies Inc.
MRM News Today: Stay Updated with the Latest MEDIROM Healthcare Technologies Inc. News in Real Time
Find MRM news now at Meyka AI. Stay informed with the latest MEDIROM Healthcare Technologies Inc. stocks updates, including price news, market analysis, and expert insights.

Top gainer LS9.SI Leader Environmental (SES) +10.00% pre-market 25 Feb 2026: volume spike signals trading interest
LS9.SI stock rises 10.00% pre-market on 25 Feb 2026 with volume 13,887,100. Meyka AI analysis and forecast included

Barclays Maintains Overweight on Vir Biotechnology, Inc. (VIR) Feb 24 2026
Barclays maintains Overweight on Vir Biotechnology (VIR) and raises target to $30. VIR analyst rating Feb 24 2026

ALNA Allena Pharmaceuticals NASDAQ Feb 2026 close $0.075, 252M vol: whatβs next
ALNA stock closed $0.075 on Feb 2026 with 252.31M shares. We analyze catalysts, valuation, and a Meyka AI forecast for investors

Jefferies Maintains Buy on The Home Depot, Inc. (HD) Feb 24 2026
Jefferies maintains Buy and lifts price target, a timely HD analyst rating update

+9.85% close: SKIN.SW Cassiopea S.p.A. (SIX) market closed, next steps
SKIN.SW stock jumps 9.85% on high volume to CHF35.70 on SIX β short-term outlook and Meyka AI forecast

Bayer (BAYN.DE XETRA) up 6.50% to β¬45.58: watch β¬42 support and analyst targets
BAYN.DE stock jumps to β¬45.58 on high volume; Meyka AI forecasts β¬49.38 monthly target for BAYN.DE stock

NVO Stock Today: February 24 β CagriSema Miss Triggers 17% Plunge
Novo Nordisk stock today plunged up to 17% after CagriSema lagged Eli Lillyβs tirzepatide, rattling OMX Copenhagen 25 and the krone. What this means for German investors, risks, and next catalysts.

KeyBanc Maintains Overweight on AMD (Advanced Micro Devices) Feb 2026
Feb 2026: KeyBanc, Evercore and Roth maintain bullish AMD analyst rating with higher price targets

XITO Xenous Holdings (PNK) volume spike 24 Feb 2026: technical overbought
XITO stock shows a volume spike on 24 Feb 2026; our analysis covers price, technicals, Meyka forecast and risk